Birinapant (TL32711)

For research use only. Not for use in humans.

目录号：S7015 中文名称：比瑞那帕

Birinapant (TL32711) Chemical Structure

CAS No. 1260251-31-7

Birinapant (TL32711)是一种SMAC模拟拮抗剂，对cIAP1最有效，无细胞试验中Kd为<1 nM，对XIAP作用较弱。Birinapant可帮助诱导HIV-1感染的细胞凋亡。Phase 2。

规格 价格 库存 购买数量  
RMB 3023.22 现货
RMB 11220.79 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Birinapant (TL32711)发表文献54篇：

产品安全说明书

IAP抑制剂选择性比较

生物活性

产品描述 Birinapant (TL32711)是一种SMAC模拟拮抗剂，对cIAP1最有效，无细胞试验中Kd为<1 nM，对XIAP作用较弱。Birinapant可帮助诱导HIV-1感染的细胞凋亡。Phase 2。
靶点
cIAP1 [1]
(Cell-free assay)		 XIAP [1]
(Cell-free assay)
<1 nM(Kd) 45 nM(Kd)
体外研究

Birinapant与XIAP和CIAP1结合的Kd分别为45 nM和 <1 nM。在TRAIL不敏感的SUM190（ErbB2的过度表达）细胞中，Birinapant独自诱导细胞死亡（IC 50约为300 nM），并显著增加TRAIL诱导的TRAIL敏感SUM149（三阴性，EGFR活化）细胞的凋亡。 Birinapant导致CIAP1迅速降解，caspase活化，PARP裂解，和NF-κB的激活。[1] Birinapant与TNF-α联用表现出强烈的体外抗黑素瘤作用。 Birinapant和TNF-α（1 ng/mL）联用抑制人黑素瘤细胞系WTH202，WM793B，WM1366和WM164生长，IC50分别为1.8，2.5，7.9和9 nM，而两种化合物单独都无效。Birinapant单独处理可诱导对WM9细胞增殖的抑制作用，IC 50为2.4 nM。Birinapant显著抑制这些细胞系中靶蛋白CIAP1和cIAP2。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PANC-1 NIjjWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv6NVc2OC9{MECvOVAxKG6P M3;Y[FAuQTZiaB?= NW\BW3R2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFraeIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1Nlk3QSd-Mk[yOVI6Pjl:L3G+
Molm13  MWTGeY5kfGmxbjDBd5NigQ>? M4H6flIwOjBxMkCwJI5O MmXTNlQhcA>? MnPK[IVkemWjc3XzJINKSVBzIHHu[EwhfG9iYTDteYNpKGync4PldkBmgHSnboSsJINKSVB{LDDhcoQhYEmDUDD1coRmeiC4YYLpc5V{KGOxbnTpeIlwdnN? M33IRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK2O|g4Lz5{NEWyOlc5PzxxYU6=
WTH202 NGW5ZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\XR5A4OiCq M33MWWlEPTB;MT64JI5ONCClb33ibY5m\CC5aYToJFFv\y:vbDDUUmYu|rF? NV7JSI1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM793B M{jsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX5No44OiCq Mo\FTWM2OD1{LkWgcm0tKGOxbXLpcoVlKHerdHigNY5oN22uIGTOSk3PuQ>? NUPUZWl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM9 NWf0[5R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvWc4hlPzJiaB?= Mn;pTWM2OD1{LkSgcm0> NVjremxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM9 NV61RnRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjxO|IhcA>? MV3JR|UxRTJwNzDuUUwh[2:vYnnu[YQhf2m2aDCxcocwdWxiVF7GMe6y MmnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N|QoRjJ|NECzOlM1RC:jPh?=
WM1366 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;pW5FkPzJiaB?= Ml2wTWM2OD15Lkmgcm0tKGOxbXLpcoVlKHerdHigNY5oN22uIGTOSk3PuQ>? Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N|QoRjJ|NECzOlM1RC:jPh?=
WM164 NIPnOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp M2fPOWlEPTB;OTDuUUwh[2:vYnnu[YQhf2m2aDCxcocwdWxiVF7GMe6y NV3TUFUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
451Lu MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3sO|IhcA>? MYjJR|UxRTF2LkKgcm0tKGOxbXLpcoVlKHerdHigNY5oN22uIGTOSk3PuQ>? NYTEPYRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM1341D NFnMVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHztWo44OiCq MX\JR|UxRTV5Lk[gcm0tKGOxbXLpcoVlKHerdHigNY5oN22uIGTOSk3PuQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zOEc,OjN2MEO2N|Q9N2F-
WM3130 NFTsSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW3NkBp NVv6elFFUUN3ME22OE4{KG6PLDDjc41jcW6nZDD3bZRpKDGwZz;tcEBVVkZvzsG= M4[1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NECzOlM1Lz5{M{SwN|Y{PDxxYU6=
WM1985 M{O2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\tV2dHPzJiaB?= M1TQSWlEPTB;OUegcm0tKGOxbXLpcoVlKHerdHigNY5oN22uIGTOSk3PuQ>? MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N|QoRjJ|NECzOlM1RC:jPh?=
WM3854 M4j5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr6W|E4OiCq NEXIbHRKSzVyPUKyOkBvVSxiY3;tZolv\WRid3n0bEAydmdxbXygWG5HNc7z NIPS[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN|Y{PCd-MkO0NFM3OzR:L3G+
MDA-MB-231 MVnDfZRwfG:6aXPpeJkh[XO|YYm= MVS3NkBpenN? MkS0R5l1d3SxeHnjbZR6KGGpYXnud5Qh[0mDUD;YTWFRNWSncHXu[IVvfCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCwMlAyKM7:TT6= NHfYTI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW4OFM6Oyd-MkW1PFQ{QTN:L3G+
A875 Mm\tR5l1d3SxeHnjbZR6KGG|c3H5 MVq3NkBpenN? MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBZUUGSLXTldIVv\GWwdDDoeY1idiCDOEe1JINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkC0JO69VS5? NYTYTpNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PFQ{QTNpPkK1OVg1Ozl|PD;hQi=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP; 

PubMed: 24526787     


Molm13 cells were cultured under standard conditions, standard conditions with mesenchymal stromal cell (MSC) coculture, or hypoxic conditions without or with MSC coculture and treated with birinapant. cIAP1, cellular inhibitor of apoptosis protein-2 (cIAP2), and X-linked inhibitor of apoptosis protein (XIAP) levels were determined by Western blot at 24 hours.

NF-κB(p65) / IκBa / Bcl-xl / NF-κB(p100) / p52; 

PubMed: 24526787     


OCI-AML3 cells were treated with birinapant (bir) for 24 hours. Protein levels in total cell lysates were determined by western blot.

BIRC2 / ARC; 

PubMed: 25079338     


Birinapant treatment decreases BIRC2 and increases ARC protein levels in AML cells and MSCs. OCI-AML3 and Molm13 cells were co-cultured with mesenchymal stem cells (MSCs) and treated with birinapant (bir). Cell lysates from OCI-AML3 and Molm13 cells were collected at 48 and 72 h by combining unattached cells and cells washed off from MSCs; lysates of MSCs were obtained from MSCs co-cultured with Molm13 cells after washing off Molm13 cells. The protein levels were determined by Western blot.

24526787 25079338
Immunofluorescence
Caspase 3/7; 

PubMed: 28665401     


MC38-Ova cells were seeded in chamber slides then overlaid with Pfn−/− OT-I T cells. After 8 h, cells were fixed, stained as indicated, then visualized by confocal microscopy. A minimum of 50 cells was counted in each condition. Error bars represent the mean±S.E.M. of triplicate determinations from a representative experiment, *P<0.05 by unpaired Student's t test.

28665401
Growth inhibition assay
Cell viability; 

PubMed: 28460471     


Cell viability was determined by CCK-8 assay. The data are representative results of three independent experiments.

28460471
体内研究 Birinapant（30毫克/千克）显著诱导恶性黑色素瘤异种移植模型451LU的肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
- 合并

荧光偏振测定法:

和化合物XIAP和CIAP1的亲和力是使用荧光底物来确定，并以Kd值表示。最初，荧光标记的修饰的Smac肽（AbuRPF -K （5-FAM）-NH 2; FP肽）的解离常数（Kd）是用固定浓度（5 nM）的肽和滴定不同浓度的蛋白质（0.075-5μM的半对数稀释）来确定。剂量-反应曲线是在5nM FP肽和50nM XIAP检测中用GraphPad Prism的单点结合模型的非线性最小二乘法生产的。各种浓度的Smac模拟物（100-0.001 μM在半对数稀释）添加到FP肽/蛋白质二元复合物，在含有100毫克/毫升牛c-球蛋白0.1M磷酸钾缓冲液中室温处理15分钟。多标签读板器采用485 nm激发滤光片和520nm的发射滤光片测量偏振值。
细胞实验：[2]
- 合并
  • Cell lines: 人黑色素瘤细胞系WM9
  • Concentrations: 1 nM-1 μM
  • Incubation Time: 3 天
  • Method: 细胞附着24小时，随后与Birinapant和/或TNF-α孵育24或72小时。随后用MTS法检测。
    (Only for Reference)
动物实验：[2]
- 合并
  • Animal Models: 人黑色素瘤异种移植451LU
  • Dosages: 30 毫克/千克
  • Administration: 每周腹腔注射3次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (123.92 mM)
Water Insoluble
Ethanol ''55 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 806.94
化学式

C42H56F2N8O6
CAS号 1260251-31-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01681368 Terminated Drug: Birinapant (TL32711) Epithelial Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 15 2012 Phase 2
NCT01486784 Terminated Drug: Birinapant Acute Myelogenous Leukemia Abramson Cancer Center of the University of Pennsylvania November 2011 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

IAP Signaling Pathway Map
Tags: 购买Birinapant (TL32711) | Birinapant (TL32711)供应商 | 采购Birinapant (TL32711) | Birinapant (TL32711)价格 | Birinapant (TL32711)生产 | 订购Birinapant (TL32711) | Birinapant (TL32711)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID